No Data
No Data
Express News | Neptunus Bioengineering Says Guangdong Provincial Government Will Be Co's Controlling Shareholder After the Deal
Express News | Neptunus Bioengineering Says Key Shareholder Shenzhen Neptunes Group Plans Sale of Stake to a Unit of Guangdong Provincial Government
Shenzhen Neptunus Bioengineering (SZSE:000078) Adds CN¥385m to Market Cap in the Past 7 Days, Though Investors From Five Years Ago Are Still Down 32%
BT Financial Report Instant Analysis: Shenzhen Neptunus Bioengineering's Q1 2024 Financial Data Comprehensive Analysis
Shenzhen Neptunus Bioengineering Co., Ltd. (stock code: 000078) is a high-tech enterprise focusing on research and development, production and sales of biomedical and health products. The company is committed to continuously improving its core competitiveness through technological innovation and product upgrades, and providing customers with high-quality health products and services. In the first quarter of 2024, Shenzhen Neptunus Bioengineering released its latest financial report, and this article will provide a detailed analysis of its financial data. The total assets of Shenzhen Neptunus Bioengineering in the first quarter of 2024 were 32.662 billion yuan, an increase of 1.11% compared to the end of the previous year. Attributable to the listed company.
Shenzhen Neptunus Bioengineering (SZSE:000078) Use Of Debt Could Be Considered Risky
Shenzhen Neptunus Bioengineering Co., Ltd.'s (SZSE:000078) Business And Shares Still Trailing The Industry
No Data